For both men and women without a Bachelor’s degree (BA), a new study in JAMA Health Forum found that mortality between 2011-2023 was markedly higher than would have been expected had death rates from 2006-2010 continued. Among 564,855 excess deaths in 2023 alone, 481,211 occurred among people without a BA—a 26 percent increase in mortality among this population, compared to pre-2010 trends. In contrast, mortality only increased by eight percent among people who received a BA. 

Marcela Maus, MD, PhD, director of the Cellular Immunotherapy Program and the Paula J. O'Keeffe Endowed Chair of the Mass General Cancer Center, is senior author and Stefanie Bailey, PhD, Hana Takei, and Giulia Escobar, PhD of the Krantz Family Center for Cancer Research at Massachusetts General Hospital are co-lead authors of a paper published in Science Translational Medicine, “IFN-g-resistant CD28 CAR-T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models.”

(WASHINGTON, June 13, 2025) – Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part of their reconstructive surgery after mastectomy were 16 times more likely to develop breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare T-cell lymphoma, compared with similar women without these genetic mutations, according to a study published today in Blood Advances.

Singapore – Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based method called "Fragle" that makes tracking cancer easier and faster using blood tests. Requiring only a small blood sample, this method analyses the size of DNA fragments in the blood to reveal distinct patterns that differentiate cancer DNA from healthy DNA, helping doctors track cancer treatment response more accurately and frequently. The research was published in Nature Biomedical Engineering in March 2025.

In recent years, the regulatory role of the gut microbiota in the initiation and progression of colorectal cancer (CRC) has attracted growing attention. Among the key microbial contributors, Fusobacterium nucleatum (Fn) has been identified as a critical pathogenic factor in CRC. As an oral anaerobic commensal, Fn is rarely found in the lower gastrointestinal tract of healthy individuals. However, under pathological conditions, it can ectopically colonize the gastrointestinal tract. Once enriched in the colorectal environment, mounting evidence suggests that Fn is involved in multiple aspects of CRC pathogenesis, including initiation, progression, metastasis, and resistance to conventional therapies such as chemotherapy, radiotherapy, and immunotherapy. A recent review by Wei Wei and Diwei Zheng's team at the Institute of Process Engineering systematically outlines the pathogenic mechanisms of Fn in CRC and summarizes both current and emerging strategies for its therapeutic targeting. Furthermore, the authors propose potential approaches to overcome existing challenges in Fn modulation, aiming to facilitate more effective therapeutic interventions and improve clinical outcomes.